Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05136846 · ClinicalTrials.gov registry record · Phase 1
Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer
A Phase 1 study of Stage III Lung Cancer AJCC v8 and Stage IIIB Lung Cancer AJCC v8, sponsored by Ohio State University Comprehensive Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
- 2
- Study locations
NCT05136846: Recruiting Phase 1 study of Stage III Lung Cancer AJCC v8 and Stage IIIB Lung Cancer AJCC v8, sponsored by Ohio State University Comprehensive Cancer Center.
NCT05136846 is a Phase 1 study of Stage III Lung Cancer AJCC v8 and Stage IIIB Lung Cancer AJCC v8 that is actively recruiting participants, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 28 participants, below the 99-participant average among 40 other Stage III Lung Cancer AJCC v8 trials with a reported enrollment target (72% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05136846, a Phase 1 study of Stage III Lung Cancer AJCC v8 and Stage IIIB Lung Cancer AJCC v8, is actively recruiting participants, sponsored by Ohio State University Comprehensive Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase I trial finds out the best dose, possible benefits and/or side effects of papaverine when given together with chemoradiation intreating patients with stage II-III non-small cell lung cancer. Papaverine targets mitochondrial metabolism to decrease the cancer growth process. Giving papaverine with chemoradiation may work best to treat patients with non-small cell lung cancer.
Primary Outcome
Will employ the Time-to-event Bayesian optimal interval design to find the MTD. Treatment-related toxicity will be assessed based on Common Terminology Criteria for Adverse Events version 5.0 criteria.
Conditions Studied
Interventions
- DRUG Carboplatin
- BIOLOGICAL Durvalumab
- DRUG Paclitaxel
- RADIATION Radiation Therapy
- DRUG Papaverine
Study Locations (2)
California
- City of Hope - Duarte
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2021-12-06 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
What NCT05136846 shows while recruiting
NCT05136846 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 99-participant average among 40 other Stage III Lung Cancer AJCC v8 trials with a reported enrollment target (72% lower).
The record links to 9 conditions, with Stage III Lung Cancer AJCC v8 appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT05136846 reports a single indexed study location in California, Ohio.
Frequently Asked Questions
What is clinical trial NCT05136846 about?
NCT05136846 is a clinical study titled "Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer". This phase I trial finds out the best dose, possible benefits and/or side effects of papaverine when given together with chemoradiation intreating patients with stage II-III non-small cell lung cancer. Papaverine targets mitochondrial metabolism to decrease the cancer growth process. Giving papaveri...
What is the current status of trial NCT05136846?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2021-12-06. Estimated completion is 2026-12-31.
What conditions does trial NCT05136846 study?
This clinical trial studies the following conditions: Stage III Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8.
What interventions are being tested in trial NCT05136846?
The interventions under investigation include: Carboplatin (DRUG), Durvalumab (BIOLOGICAL), Paclitaxel (DRUG), Radiation Therapy (RADIATION), Papaverine (DRUG).
Who is sponsoring clinical trial NCT05136846?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05136846 being conducted?
This trial has 2 study locations across California, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage III Lung Cancer AJCC v8
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05136846's enrollment target sits among peer trials
28 31st of 40 higher than 8 of 40 other Stage III Lung Cancer AJCC v8 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stage III Lung Cancer AJCC v8 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
RECRUITING · Phase 1
-
Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors
ACTIVE NOT RECRUITING · Phase 1
-
CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI